Table 3.
The concentration of salivary and erythrocytes/plasma Aβ, LF, IL-1β and IL-1β in patients with Alzheimer’s disease and the control group.
| Biomarker | Saliva | Erythrocytes/Plasma | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| C | AD | P-value | C | AD | P-value | |||||
| Median (minimum–maximum) | 25–75% Percentile | Median (minimum–maximum) | 25–75% Percentile | Median (minimum–maximum) | 25–75% Percentile | Median (minimum–maximum) | 25–75% Percentile | |||
| Aβ (AFU/mg protein) | 5049 (678.7–6512) | 3691–5476 | 7236 (5402–18,396) | 6351–9299 | < 0.0001 | 70,487 (26,787–85,117) | 56,906–74,762 | 70,948 (33,935–102,063) | 60,802–78,992 | 0.5405 |
| LF (μg/mg protein) | 29.97 (12.32–42.57) | 23.81–35.36 | 24.52 (9.866–45.34) | 21.17–45.34 | 0.0211 | – | ||||
| IL-1β (ng/mg protein) | 70.85 (46.24–96.09) | 63.21–75.44 | 88.47 (55.21–155.3) | 78.29–101.4 | < 0.0001 | 25.6 (13.39–37.09) | 20.32–30.28 | 44.26 (24.32–73.17) | 39.5–46.29 | 0.0092 |
C—control group; AD—Alzheimer’s disease; Aβ—amyloid beta, LF—lactoferrin; IL-1β—Interleukin 1 Beta.